In terms of recent efficacy, we can find that Rh-endostatin combined with synchronous radiotherapy can effectively increase the complete remission rate of cervical cancer, and compared with synchronous radiotherapy intervention alone, Rh-endostatin combined with synchronous chemotherapy can induce more cervical cancer patients to achieve complete remission, and Rh-endostatin can inhibit angiogenesis, blocking the supply of nutrients and nutrients to tumor cells, and achieve the purpose of killing tumor cells. The gene discussed is COL18A1; the disease is cervical carcinoma.